These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 16492205)

  • 1. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
    Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
    Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
    Linnebjerg H; Park S; Kothare PA; Trautmann ME; Mace K; Fineman M; Wilding I; Nauck M; Horowitz M
    Regul Pept; 2008 Nov; 151(1-3):123-9. PubMed ID: 18675854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
    Taylor K; Kim D; Nielsen LL; Aisporna M; Baron AD; Fineman MS
    Horm Metab Res; 2005 Oct; 37(10):627-32. PubMed ID: 16278786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
    Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
    Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers.
    Pinelli NR; Jantz A; Smith Z; Abouhassan A; Ayar C; Jaber NA; Clarke AW; Commissaris RL; Jaber LA
    J Clin Pharmacol; 2011 Feb; 51(2):165-72. PubMed ID: 20484613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
    Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
    Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects.
    Blase E; Taylor K; Gao HY; Wintle M; Fineman M
    J Clin Pharmacol; 2005 May; 45(5):570-7. PubMed ID: 15831781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
    Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
    Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
    Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
    Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
    Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.
    Gredal C; Rosenfalck A; Dejgaard A; Hilsted J
    Diabetes Res Clin Pract; 2008 May; 80(2):293-8. PubMed ID: 18304675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
    Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
    Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial.
    Perriello G; Pampanelli S; Porcellati F; Avogaro A; Bosi E; Petrella G; Squatrito S; Furneri S; Marra G; Vitali L; Previti M; Cucinotta D
    Diabet Med; 2005 May; 22(5):606-11. PubMed ID: 15842516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study.
    Guevara-Aguirre J; Guevara M; Saavedra J; Mihic M; Modi P
    Diabetes Metab Res Rev; 2004; 20(6):472-8. PubMed ID: 15386822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.
    Fineman MS; Shen LZ; Taylor K; Kim DD; Baron AD
    Diabetes Metab Res Rev; 2004; 20(5):411-7. PubMed ID: 15343588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
    Schwartz S; Zagar AJ; Althouse SK; Pinaire JA; Holcombe JH
    Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.